Navigation Links
Yongye Biotechnology International Raises $ 9.0 Million In Private Placement, Raises Guidance
Date:5/8/2009

BEIJING, May 8 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB, "Yongye" or the "Company"), a leading developer and distributor of plant and animal nutrient products in the People's Republic of China, today announced that it closed a private placement financing with institutional and other accredited investors which included many of the same investors who participated in its April and September 2008 financings. Gross proceeds of approximately $9.0 million were generated through the issuance of 5.83 million shares of common stock at $1.54 per share. ROTH Capital Partners served as the placement agent.

The Company sells most of its Shengmingsu brand products to a limited number of independent regional distributors which then sell the products to local distributors and approximately 3,500 Yongye branded and other retail stores. Beginning in late 2008, the independent regional distributors started receiving new orders from their local distributors and retail stores for an increasing volume of Yongye products to be delivered in 2009. These additional orders led Yongye to seek additional financing. The Company plans to use the proceeds of the current private placement as working capital to help ensure that it can fill all of the orders it has already received and continues to receive from the independent distributors.

Revised Revenue and Net Income Guidance

Yongye is raising its previously announced revenue and net income guidance because of increased sales supported by this current financing. Yongye revises its previously announced revenue guidance for fiscal year 2009 from $66 million to $82 to $84 million, and its previously announced net income guidance from $15.8 million to $23 to $24 million.

"We undertook great effort in 2008 to build up Yongye's marketing and technical support functions so that they could support, scale with
'/>"/>

SOURCE Yongye Biotechnology International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day
2. Yongye Biotechnology Announces Preliminary Results for its Fiscal Quarter Ended March 31, 2009
3. Yongye Biotechnology Appoints New Chief Financial Officer
4. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
5. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
6. Yongye Biotechnology International to Expand its Network of Branded Stores
7. Yongye Biotechnology to Present at Roth Conference
8. Yongye Biotechnology Announces Record Third Quarter Results
9. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
10. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
11. Yongye Biotechnology International Raises $9.4 Million in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... RMI specializes in Stemnexa™ ... such as meniscal tears, ACL injuries, rotator cuff ... due to degenerative conditions like osteoarthritis. Stemnexa ... promote better post-surgical outcomes. , Stemnexa combines the ... marrow harvesting with two complimentary cellular technologies: Bone ...
(Date:3/4/2015)... SANTA BARBARA, CALIFORNIA (PRWEB) March 04, 2015 ... regulatory consulting firm in the life sciences industry, hired ... Compliance. Blewitt leads the Cloud Compliance Services and ... sciences companies utilize cloud based applications while maintaining compliance ... 20 years, Blewitt has been an accomplished life sciences ...
(Date:3/4/2015)... Proove Biosciences , a commercial ... to announce the launch of their CME-accredited course ... of Pain”. , The continuing medical education program ... year. The focus of the program is to ... treatments, integrate appropriate pain management techniques, and incorporate ...
(Date:3/4/2015)... 2015 Launched by the ... in December 2011, ,SARAH, - the French ... versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled ... SARAH, a large French study of patients ... HCC) has completed patient enrolment, exceeding its 400-patient target, ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... LOS ANGELES, Oct. 13 Vista Partners announced ... Bio Medica Corporation,(Nasdaq: ABMC ) and maintains ... Director of Research at Vista Partners stated, "Sales,internationally ... lab,alliance, which give ABMC,s products exposure in numerous ...
... Houston-based Proximity Systems ... WorkStations: one year ... installing 400,Proximity Systems Computer WorkStations, Centerpoint Medical Center offers,favorable ... workstations are satisfying the needs of the,hospital,s nurses, physicians, ...
... October 13 The International Diabetes,Federation (IDF) announced today ... for action to secure care for the thousands of ... The meeting, Access to Essential Diabetes Medicines for ... October 25 in London, United,Kingdom. The International Diabetes Federation ...
Cached Biology Technology:Vista Partners Updates Coverage; Maintains $3.20 Target Price 2In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care 2In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care 3In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care 4International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 2International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 3
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... that certain genes can influence a person,s likelihood to ... the Masonic Cancer Center, University of Minnesota demonstrates that ... survive the disease. ... has successfully identified combinations of genes associated with early ...
... French . Maputo, MozambiqueThe ... research programme designed to understand the relationship between ... services. The decision was made today at the ... (ICSU) and should help provide the scientific knowledge ...
... Evolved Machines, Inc. has,been selected as ... Advanced Research,Projects Agency (DARPA) program to engineer ... recognition. The $5.1 million,dollar contract will integrate ... a highly versatile and sensitive broad-spectrum device ...
Cached Biology News:U of MN study shows link between gene variations and cancer survival 2ICSU launches new program to understand the human impact on Earth's life-support systems 2
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (R3776) ... assistance. Material: cap polystyrene ...
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Yeast Display Vector is specifically designed to ... surface of Saccharomyces cerevisiae. Displayed proteins can ... with known or putative ligands. pYD1 uses ... of two domains, Aga1 and Aga2, to ...
... pump series combines Harvard Apparatuss best pump mechanism, ... wide range of configuration options. A lookup table ... syringes from all the major manufacturers. A bright, ... pertinent information from across the lab. All models ...
Biology Products: